High concentration formulation

A method of treating androgenetic alopecia, the method comprising topically administering to a subject in need thereof, an effective amount of a pharmaceutical formulation comprising:

• a) cortexolone-17α-propionate at a concentration of about 5 weight percent to about 15 weight percent,
• b) a pharmaceutically acceptable amount of one or more pharmaceutically acceptable solvents, and
• c) less than about 5% water,
• wherein:
• the cortexolone-17α-propionate is fully solubilized in the formulation;
• the formulation has a pH between about 4 and about 5;
• and
• wherein the formulation has a storage stability of at least about 6 months at room temperature as measured by the formulation comprising less than 5 weight percent of cortexolone-21-propionate (17α-hydroxy-21-propionyloxy-pregna-4-ene-3,20-dione) or other degradation products.